Departments of Radiology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.
AJNR Am J Neuroradiol. 2011 Aug;32(7):1195-201. doi: 10.3174/ajnr.A2501. Epub 2011 Jul 14.
Tumor hypoxia is a known factor of radioresistance in HNSCC. CTP is a noninvasive method of measuring tumor perfusion in vivo. The purpose of our study was to determine serial changes in tumor perfusion in HNSCC during a course of RT by using CTP and to correlate tumor perfusion measurements to LRC.
A prospective study was performed in 15 patients with HNSCC receiving definitive RT who underwent serial CTP before RT; at weeks 2, 4, and 6 of RT; and 6 weeks after RT. The median follow-up was 28 months (range, 6-44 months). Thirteen patients achieved LRC, and 2 patients had LRF. Tumor perfusion parameters, including BF, BV, MTT, and CP, were obtained by using a deconvolution-based analysis.
Pretreatment tumor BF was significantly higher in patients who achieved LRC, 118.0 mL/100 g/min, compared with those with LRF, 53.4 mL/100 g/min (P = .004). Similarly, pretreatment CP was higher in patients with LRC, 16.6 mL/100 g/min, compared with those with LRF, 7.7 mL/100 g/min (P = .02). At week 2 of RT, tumor BF parameters showed a 27.5% increase versus an 18.1% decrease from pretreatment BF values (P = .046) in patients with LRC and LRF, respectively. A decrease in BF and BV was observed in both groups 6 weeks after RT compared with these values at baseline scanning.
An increase in tumor BF and CP by using CTP early during a course of RT predicts LRC in patients with HNSCC treated with RT.
肿瘤缺氧是头颈部鳞状细胞癌(HNSCC)放射抵抗的已知因素。CTP 是一种活体测量肿瘤灌注的非侵入性方法。我们的研究目的是通过 CTP 确定 HNSCC 患者在放射治疗过程中肿瘤灌注的连续变化,并将肿瘤灌注测量结果与局部控制(LRC)相关联。
对 15 例接受根治性放射治疗的 HNSCC 患者进行了前瞻性研究,这些患者在放射治疗前;放射治疗第 2、4 和 6 周;以及放射治疗后 6 周进行了连续 CTP。中位随访时间为 28 个月(范围,6-44 个月)。13 例患者达到 LRC,2 例患者出现 LRF。通过基于解卷积的分析获得肿瘤灌注参数,包括 BF、BV、MTT 和 CP。
在达到 LRC 的患者中,预处理肿瘤 BF 显著高于出现 LRF 的患者,分别为 118.0 毫升/100 克/分钟和 53.4 毫升/100 克/分钟(P =.004)。同样,在达到 LRC 的患者中,预处理 CP 也高于出现 LRF 的患者,分别为 16.6 毫升/100 克/分钟和 7.7 毫升/100 克/分钟(P =.02)。在放射治疗第 2 周,与 LRC 和 LRF 患者的预处理 BF 值相比,BF 参数分别增加了 27.5%和降低了 18.1%(P =.046)。在放射治疗后 6 周,两组的 BF 和 BV 均较基线扫描时降低。
在接受放射治疗的 HNSCC 患者中,CTP 早期显示肿瘤 BF 和 CP 增加可预测 LRC。